

6 September 2024

Dear registered shareholder(s),

**Notice of Publication of 2024 Interim Report (the “Current Corporate Communication”)  
and Arrangement of Electronic Dissemination of Corporate Communications**

The English and Chinese versions of the Current Corporate Communication of Everest Medicines Limited (the “Company”) are available on the Company’s website at [www.everestmedicines.com](http://www.everestmedicines.com) and the website of Hong Kong Exchanges and Clearing Limited (“HKEx”) at [www.hkexnews.hk](http://www.hkexnews.hk). For the shareholders who have selected to receive the Company’s Corporate Communications in printed version, enclosed is the Current Corporate Communication of the Company in the language you have expressly chosen to receive. If you have any difficulty in receiving or gaining access to the Current Corporate Communication posted on the Company’s website for any reason, the Company will promptly upon your request send the printed version of the Current Corporate Communication to you free of charge; please write to the Company’s share registrar in Hong Kong (the “Hong Kong Share Registrar”), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong or by email to [everestmedicines.ecom@computershare.com.hk](mailto:everestmedicines.ecom@computershare.com.hk).

**Arrangement of Electronic Dissemination of Corporate Communications**

Pursuant to Rule 2.07A of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) under the expansion of the paperless listing regime and electronic dissemination of corporate communications that came into effect on 31 December 2023, the Company is writing to inform you that the Company has adopted electronic dissemination of corporate communications (the “Corporate Communications”). Corporate communications refer to any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the directors’ report, its annual accounts together with a copy of the auditors’ report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular; and (f) a proxy form.

Please note that both the English and Chinese versions of all future Corporate Communications will be available electronically on the website of the Company at [www.everestmedicines.com](http://www.everestmedicines.com) and the website of HKEx at [www.hkexnews.hk](http://www.hkexnews.hk) in place of printed copies.

**Solicitation of electronic contact details**

To ensure timely receipt of the Actionable Corporate Communications<sup>(Note)</sup>, the Company recommends you to provide your email address by scanning your personalized QR code printed on the enclosed reply form (the “Reply Form”). Alternatively, you may sign and return the Reply Form to the Hong Kong Share Registrar, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong.

**If the Company does not receive a functional email address in your reply, until such time that the functional email address is provided to the Hong Kong Share Registrar, the Company will send the Actionable Corporate Communications<sup>(Note)</sup> in printed form to you in the future.**

If you want to receive the future Corporate Communications in printed form, please complete and return the Reply Form on the reverse side to the Hong Kong Share Registrar or send an email to [everestmedicines.ecom@computershare.com.hk](mailto:everestmedicines.ecom@computershare.com.hk) specifying your name, address and request to receive the future Corporate Communications in printed form. Please note that such instruction shall be valid for one year starting from the receipt date of your instruction and will expire thereafter.

Should you have any queries relating to this letter, please send an email to the Hong Kong Share Registrar at [everestmedicines.ecom@computershare.com.hk](mailto:everestmedicines.ecom@computershare.com.hk).

Yours faithfully,  
By order of the Board  
**Everest Medicines Limited**  
**Wei Fu**  
Chairman and Executive Director

*Note: Actionable Corporate Communication is any corporate communication that seeks instructions from Company’s securities holders on how they wish to exercise their rights or make an election as the issuer’s securities holder.*

各位登記股東：

**2024 年中期報告（「本次公司通訊」）之發布通知及以電子方式發布公司通訊之安排**

雲頂新耀有限公司（「本公司」）本次公司通訊的中、英文版本已上載於本公司網站 [www.everestmedicines.com](http://www.everestmedicines.com) 及香港交易及結算所有限公司（「香港交易所」）網站 [www.hkexnews.hk](http://www.hkexnews.hk)。若閣下之前選擇收取本公司公司通訊之印刷版本，現向閣下奉上按照閣下之前所選擇語言編製的本次公司通訊。閣下若因任何理由以致在收取或接收載於本公司網址上的本次公司通訊出現困難，本公司將於接到閣下通知後，盡快向閣下免費發送有關本次公司通訊的印刷本；閣下可以書面方式通知本公司的香港股份過戶登記處（「香港股份過戶處」）香港中央證券登記有限公司，地址為香港灣仔皇后大道東 183 號合和中心 17M 樓，或電郵至 [everestmedicines.ecom@computershare.com.hk](mailto:everestmedicines.ecom@computershare.com.hk)。

**以電子方式發布公司通訊之安排**

根據自 2023 年 12 月 31 日起生效的香港聯合交易所有限公司證券上市規則（「上市規則」）第 2.07A 條下擴大無紙化上市機制及以電子方式發布公司通訊規定，本公司謹此通知閣下，本公司已採用以電子方式發布公司通訊（「公司通訊」）之安排。公司通訊是指本公司為向其任何證券持有人提供資訊或提醒其採取行動而發布或將要發布的任何文件，包括但不限於(a) 董事報告、年度帳目以及審計報告副本以及（如適用）財務摘要報告；(b) 中期報告及其中期報告摘要（如適用）；(c) 會議通知；(d) 上市文件；(e) 通函；和 (f) 委任代表表格。

請注意，所有未來公司通訊的英文版和中文版將在公司網站 [www.everestmedicines.com](http://www.everestmedicines.com) 和香港交易所網站 [www.hkexnews.hk](http://www.hkexnews.hk) 上提供，以代替印刷本。

**徵集電子聯絡資料**

為確保及時收到可供採取行動的公司通訊<sup>(附註)</sup>，本公司建議閣下透過掃描本函背頁之回條（「回條」）上列印的閣下專屬二維碼來提供閣下的電子郵件地址。或者，閣下也可以簽署回條並交回香港股份過戶處香港中央證券登記有限公司，地址為香港灣仔皇后大道東 183 號合和中心 17M 樓。

**如果本公司沒有收到閣下的有效電子郵件地址，直至香港股份過戶處收到閣下有效的電子郵件地址前，本公司未來將以印刷本形式發送可供採取行動的公司通訊<sup>(附註)</sup>。**

若閣下希望收取公司通訊之印刷版，請填妥本函背頁之回條並交回香港股份過戶處，或發送電子郵件至 [everestmedicines.ecom@computershare.com.hk](mailto:everestmedicines.ecom@computershare.com.hk)，並註明閣下的姓名、地址以及收取公司通訊印刷版的要求。請注意，收取未來公司通訊印刷版之指示由收悉閣下指示當日起計一年內有效，此後將過期。

如閣下對本函件有任何疑問，請發送電子郵件至 [everestmedicines.ecom@computershare.com.hk](mailto:everestmedicines.ecom@computershare.com.hk) 與香港股份過戶處聯絡。

承董事會命  
**雲頂新耀有限公司**  
主席兼執行董事  
**傅唯**  
謹啟

2024 年 9 月 6 日

附註：可供採取行動的公司通訊指任何涉及及要求公司的證券持有人指示其擬如何行使其有關證券持有人的權利或作出選擇的公司通訊。

